Taken together, these results demonstrate that C1-27 targets GSTO1 in tumours and shows promising antitumour activity in both cell line xenograft and PDX models of colorectal cancer, without gross systemic toxicities. This evidence concerns the gene GSTO1 and colorectal cancer.